Álvarez-Guisasola, FernandoOrozco-Beltrán, DomingoCebrián-Cuenca, Ana MRuiz Quintero, Manuel AntonioAngullo Martínez, EscarlataÁvila Lachica, LuisOrtega Millán, CarlosCaride Miana, ElenaNavarro-Pérez, JorgeSagredo Perez, JulioBarrot de la Puente, JoanCos Claramunt, Francesc Xavier2023-01-252023-01-252019-07-15http://hdl.handle.net/10668/14259Treatment of diabetes mellitus type2 (DM2) includes healthy eating and exercise (150minutes/week) as basic pillars. For pharmacological treatment, metformin is the initial drug except contraindication or intolerance; in case of poor control, 8 therapeutic families are available (6 oral and 2 injectable) as possible combinations. An algorithm and some recommendations for the treatment of DM2 are presented. In secondary cardiovascular prevention, it is recommended to associate an inhibitor of the sodium-glucose cotransporter type 2 (iSGLT2) or a glucagon-like peptide-1 receptor agonist (arGLP1) in patients with obesity. In primary prevention if the patient is obese or overweight metformin should be combined with iSGLT2, arGLP1, or inhibitors of type4 dipeptidylpeptidase (iDPP4). If the patient does not present obesity, iDPP4, iSGLT2 or gliclazide, sulfonylurea, recommended due to its lower tendency to hypoglycaemia, may be used.esAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Antidiabetic drugsDiabetes tipo 2Fármacos antidiabéticosHiperglucemiaHyperglycemiaType 2 diabetesAlgorithmsDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsDrug Therapy, CombinationHumansHyperglycemiaHypoglycemic AgentsMetforminObesitySodium-Glucose Transporter 2Sodium-Glucose Transporter 2 Inhibitorsresearch article31320123open access10.1016/j.aprim.2019.05.0141578-1275PMC6836897https://doi.org/10.1016/j.aprim.2019.05.014https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836897/pdf